GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for HART

HART

Official Title

The Homocysteine and Atherosclerosis Reduction Trial (HART)

Status

Completed

Overview

To evaluate the effects of homocysteine-lowering vitamin therapy on the progression of carotid atherosclerosis, as evaluated by serial B-mode quantitative ultrasound (US) examinations. A substudy of the HOPE-2 trial.

Study Design

Randomized, double-blind, multicenter, international, placebo-controlled trial

Primary Endpoint

The primary study outcome was the composite of CV death, myocardial infarction and stroke.

Number of Patients

923

Number of Sites

10

Number of Countries

1

Study Period

2000

Principal Investigator

Eva Lonn

Program Manager

Jackie Bosch

Research Coordinator

Not Applicable

Key Publications

  • Held C, Sumner G, Sheridan P, McQueen M, Smith S, Dagenais G, Yusuf S, Lonn E. Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vasc Med. 2008 Nov;13(4):245-53. doi: 10.1177/1358863X08092102.